Keros Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Keros Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 44.6 times by its yearly operating cash. Higher than 94% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.2 times its market value (net cash). Higher than 91% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-29.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 64% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
44.6×Debt due within a year is covered 44.6 times by its yearly operating cash.
Higher than 94% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× cashCash, after subtracting all debt, is 1.2 times its market value (net cash).
Higher than 91% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Keros Therapeutics, Inc. made a loss over the last year. Keros Therapeutics, Inc. owes $0.09 for every $1 it owns. Keros Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKeros Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.86The share price is 0.86 times Keros Therapeutics, Inc.'s book value per share, lower than 82% of Healthcare companies in United States.
Market cap
$225 MThe total market value of all of Keros Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$262 MWhat Keros Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$13.23Net worth divided by the number of shares. The share price of $11.35 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-17.2%Keros Therapeutics, Inc. lost 17.2% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
Owes vs Owns
0.09×Keros Therapeutics, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Dividend yield
NoneKeros Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+6775%Revenue rose 6775% in the year to Dec 2025.
Profit growth
Back to profitKeros Therapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
35.7%Keros Therapeutics, Inc. keeps $36 of every $100 of revenue as net profit.
Cash quality
1.2×Cash from Keros Therapeutics, Inc.'s business was 1.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashKeros Therapeutics, Inc. held $271 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Keros Therapeutics, Inc.: $225 M ÷ $262 M (30 Jun 2026) = 0.9.
What is Keros Therapeutics, Inc.'s return on equity?
Keros Therapeutics, Inc. lost 17.2% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
How much does Keros Therapeutics, Inc. owe compared with what it owns?
Keros Therapeutics, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Does Keros Therapeutics, Inc. pay a dividend?
No. Keros Therapeutics, Inc. does not currently pay a dividend.
Is Keros Therapeutics, Inc.'s revenue growing?
Revenue rose 6775% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.